Ildong, KR7249420001

Ildong stock tracks an oncology deal as revenue rises 6.8 percent

Published on 10/04/2026 at 12:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ildong stock was last at KRW 14,510 on October 2, 2026, as the company pursued a 13.95 percent Idience stake. Q2 revenue rose 6.8 percent year over year.

Ildong, KR7249420001, Illustration mit AI erstellt.

Ildong stock (ISIN KR7249420001) was last at KRW 14,510 on the KOSPI on October 2, 2026, at 3:30 p.m. KST, down 0.41 percent from the prior session. The company is pursuing a KRW 36.76 billion investment for a 13.95 percent stake in Idience, putting oncology assets at the center of the latest valuation debate.

Idience deal adds oncology exposure

According to IT Boltwise on October 2, 2026, Ildong agreed to acquire 7,097,016 redeemable convertible preferred shares in Idience. The transaction is split into KRW 2.00 billion for 400,000 shares on October 7, 2026, and KRW 34.76 billion for 6,697,016 shares on October 15, 2026.

The target company is developing benadaparib, a PARP1 inhibitor, giving Ildong a direct link to oncology development and possible licensing activity. The structure is an investment in existing shares rather than a capital increase at Idience, according to IT Boltwise.

Revenue grows but margins stay narrow

Ildong reported Q2 2026 revenue of KRW 147.86 billion, up 6.8 percent from the year-earlier quarter, while operating profit reached KRW 3.62 billion. The quarterly operating margin was 2.45 percent, down from 6.63 percent in Q1 2026, making execution and commercialization central to the investment case.

The Q2 figures are also published by ATS View, which reports revenue of KRW 148 billion, year-over-year growth of 6.8 percent and operating profit of KRW 2.0 billion. The difference reflects reporting precision and presentation, while both sources show stronger sales alongside a much thinner margin than in the first quarter.

Stock remains below yearly high

Ildong stock had a 52-week range of KRW 11,250 to KRW 45,050 on October 2, 2026, with volume of 136,276 shares and market capitalization of KRW 457.2 billion. The reference price was 67.79 percent below the 52-week high, so the Idience investment must eventually translate into pipeline progress and earnings support to change the stock's valuation profile.